Cancer Vaccine Partnering Terms and Agreements

231 pages report Published in
Pharmaceuticals
Publisher: Current Partnering

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer vaccine partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer vaccine partnering contract documents
  • Top cancer vaccine deals by value

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 200 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma, big biotech and most active dealmakers in cancer vaccine partnering.

Chapter 3 provides a review of the leading cancer vaccine deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2009. This report comes with an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z, deal type and stage of development.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

Report scope

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

  • Trends in cancer vaccine dealmaking in the biopharma industry since 2009
  • Analysis of cancer vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 200 cancer vaccine deal records
  • The leading cancer vaccine deals by value since 2009
  • Includes adjuvant and drug delivery deals and alliances since 2009

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 500 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Cancer Vaccine Partnering Agreements provides the reader with the following key benefits:

  • In-depth understanding of cancer vaccine deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Acces to the structure of cancer vaccine agreements with numerous real life case studies
  • Comprehensive access to over 200 actual cancer vaccine deals entered into by the world’s biopharma companies
  • Insight into the terms included in a cancer vaccine agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in cancer vaccine dealmaking
2.1. Introduction
2.2. Cancer vaccine partnering over the years
2.3. Big pharma cancer vaccine dealmaking activity
2.3. Big biotech cancer vaccine dealmaking activity
2.4. Most active in cancer vaccine partnering
2.5. Cancer vaccine partnering by deal type
2.6. Cancer vaccine partnering by stage of development
2.7. Cancer vaccine partnering by cancer indication
2.8. Disclosed deal terms for cancer vaccine partnering
2.8.1 Cancer vaccine partnering headline values
2.8.2 Cancer vaccine deal upfront payments
2.8.3 Cancer vaccine deal milestone payments
2.8.4 Cancer vaccine royalty rates
2.9. The anatomy of cancer vaccine partnering
2.9. The anatomy of a cancer vaccine deal
2.9. a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012
2.9. b. Case study 2: University of Pennsylvania- VGX Pharmaceuticals: April 24, 2007

Chapter 3 – Leading cancer vaccine deals
3.1. Introduction
3.2. Top cancer vaccine deals by value

Chapter 4 – Cancer vaccine dealmaking directory
4.1. Introduction
4.2. Company A-Z
A*STAR Bioprocessing Technology Institute
Adamis Pharmaceuticals
Adjuvantix
AdnaGen
Aduro BioTech
Advaxis
Affitech
Agenus Bio
Agilent Technologies
Aldevron
Alexis Biotech
Alnylam Pharmaceuticals
AnGes MG
Antigen Express
Antigenics
Argos Therapeutics
Ariad Pharmaceuticals
Asterias Biotherapeutics
Astrimmune
Averion
Bavarian Nordic
Bayer Innovation
Baylor College
Baylor College of Medicine
Baylor Research Institute
Beijing Genomics Institute (BGI)
Bellicum Pharmaceuticals
Beth Israel Deaconess Medical Center
BinnoPharm
Bio-Matrix Scientific
BioAlliance Pharma
BioSante Pharmaceuticals
BioTime
BioVest
BioWa
Bristol-Myers Squibb
Broadvector
Brown University
Cadila Pharmaceuticals
Cancer Prevention and Research Institute of Texas
Cancer Research Institute
Cancer Research Technology
Cancer Research UK
Cancer Research Wales
Cardiff University
Catherex
Cedars-Sinai Medical Center
Champions Oncology
ChemRar High-Tech Center
City of Hope
Cleveland BioLabs
Clinipace Worldwide
Cobra Biologics
Colby Pharmaceuticals
CSIRO
CSL
CureLab Oncology
CureVac
Daiichi Sankyo
Dalton Pharma Services
Dana-Farber Cancer Institute
DCPrime
Delta-Vir
Dendreon
Department of Defense
Diosynth
Dynavax Technologies
Encorium Group
Entest BioMedical
European Union
Federal Ministry of Education and Research (BMBF)
Formatech
Forska and Vax
Fraunhofer Institute for Cell Therapy and Immunology
Fred Hutchinson Cancer Research Center
G-Con
Galena Biopharma
Genentech
Generex Biotechnology
Genetic Immunity
GenoLac
Genomic Expression
German Cancer Research Center
GlaxoSmithKline
Gradalis
Gynecologic Oncology Group
Heat Biologics
HemaCare
HemispheRx Biopharma
IBio
Ichor Medical Systems
Immatics Biotechnologies
Immune Design
ImmuneRegen BioSciences
Immunicum
ImmunoCellular Therapeutics
Immunomedics
Immunotope
Immunovaccine
ImmunoVaccine Technologies
Immunovo
Inovio Pharmaceuticals
InteRNA Technologies
IRX Therapeutics
ISSI-Strategy
Jaiva Technologies
Janssen Pharmaceuticals
Jantibody Therapeutics
Japan Vaccine
Jennerex
John Hopkins University School of Medicines
Johns Hopkins University
JSC Binnopharm
Juvaris BioTherapeutics
KAEL-GemVax
KellBenx
Kirin Pharma
Kyowa Hakko Kirin
Lipoxen
London Genetics
Ludwig Institute for Cancer Research
MabVax Therapeutics
Mary Crowley Cancer Research Center
Mayo Clinic
MD Anderson Cancer Center
Medarex
MediGene
MedImmune
Memorial Sloan Kettering Cancer Center
Merck and Co
Merck KGaA
Merck Serono
Merix Bioscience
Methodist Hospital Research Institute
Ministry of Industry and Trade of the Russian Federation
MorphoSys
Mount Sinai School of Medicine
Nanobiotix
National Cancer Institute
National Cancer Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
National Research Council Canada
NeoStem
NewVac
Northwest Biotherapeutics
Norwegian Research Council
Nottingham City Council
Novartis
Novavax
Numoda
NYU Langone Medical Center
Ohio State University
Omnimmune
OncoPep
OncoSec Medical
Oncotherapy Science
Oncothyreon
Oncovir
Ono Pharmaceutical
Opsona Therapeutics
Oxford BioMedica
Oxford Immunotec
Panacela Labs
Pepscan Therapeutics
Pfenex
Pfizer
Pharmsynthez
Pique Therapeutics
Pro-Cure Therapeutics
Progenitor Cell Therapy
Prostate Cancer Foundation (PCF)
PsiOxus Therapeutics
Qiagen
Radboud University Nijmegen Medical Centre
Radient Pharmaceuticals
Regen BioPharma
Roche
RXi Pharmaceuticals
Scancell
SOTIO
Stellar Biotechnologies
Stellar Pharmaceuticals
Stemline Therapeutics
Symphony Dynamo
TapImmune
Tasly Pharmaceuticals
Technomark Life Sciences
Teva Pharmaceutical Industries
The Regents of the University of California
Therinject
ToleRx
Torrey Pines Institute for Molecular Studies
Transgene
UK Government
University of Connecticut
University of Copenhagen
University of Miami
University of Pennsylvania
University of Pennsylvania School of Veterinary Medicine
University of Pittsburgh
University of Queensland
University of Rouen
University of Western Ontario
Vaccibody
Vaccinogen
Vaxil BioTherapeutics
Vaximm
Vinnova
ViroMed
Vivalis
VLST Corporation
VU University Amsterdam
Wistar Institute
Xencor
4.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
4.4. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Research
Sub-license
Supply
Technology transfer
Termination
Warranty
4.5. By oncology therapy area
Oncology
4.6. Cancer deals by related technology
Vaccines
Adjuvants

Chapter 5 –Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Technology Reports
Order Form – Reports

List of Figures

Figure 1: Cancer vaccine partnering since 2009
Figure 2: Big pharma – top 50 – cancer vaccine deals 2009 to 2014
Figure 3: Big pharma cancer vaccine deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – cancer vaccine deals 2009 to 2014
Figure 5: Big biotech cancer vaccine deal frequency – 2009 to 2014
Figure 6: Active cancer vaccine dealmaking activity– 2009 to 2014
Figure 7: Cancer vaccine partnering by deal type since 2009
Figure 8: Cancer vaccine partnering by stage of development since 2009
Figure 9: Vaccine partnering by oncology target since 2009
Figure 10: Cancer vaccine deals with a headline value – by stage of development
Figure 11: Cancer vaccine deal headline value distribution, US$million – discovery stage
Figure 12: Cancer vaccine deal headline value distribution, US$million – preclinical stage
Figure 13: Cancer vaccine deal headline value distribution, US$million – phase I stage
Figure 14: Cancer vaccine deal headline value distribution, US$million – phase II stage
Figure 15: Cancer vaccine deal headline value distribution, US$million – phase III stage
Figure 16: Cancer vaccine deal headline value distribution, US$million – regulatory stage
Figure 17: Cancer vaccine deal headline value distribution, US$million – marketed stage
Figure 18: Cancer vaccine deal headline value – median value by stage of development
Figure 19: Cancer vaccine deals with upfront payment values – by stage of development
Figure 20: Cancer vaccine deal upfront value distribution, US$million – discovery stage
Figure 21: Cancer vaccine deal upfront value distribution, US$million – preclinical stage
Figure 22: Cancer vaccine deal upfront value distribution, US$million – phase I stage
Figure 23: Cancer vaccine deal upfront value distribution, US$million – phase II stage
Figure 24: Cancer vaccine deal upfront value distribution, US$million – phase III stage
Figure 25: Cancer vaccine deal upfront value distribution, US$million – regulatory stage
Figure 26: Cancer vaccine deal upfront value distribution, US$million – marketed stage
Figure 27: Cancer vaccine deal upfront payment value – median value by stage of development
Figure 28: Cancer vaccine deals with milestone payment – by stage of development
Figure 29: Cancer vaccine deal milestone value distribution, US$million – discovery stage
Figure 30: Cancer vaccine deal milestone value distribution, US$million – preclinical stage
Figure 31: Cancer vaccine deal milestone value distribution, US$million – phase I stage
Figure 32: Cancer vaccine deal milestone value distribution, US$million – phase II stage
Figure 33: Cancer vaccine deal milestone value distribution, US$million – phase III stage
Figure 34: Cancer vaccine deal milestone value distribution, US$million – regulatory stage
Figure 35: Cancer vaccine deal milestone value distribution, US$million – marketed stage
Figure 36: Cancer vaccine deals with royalty rates-by stage of development
Figure 37: Cancer vaccine deal royalty rate value distribution, US$million – discovery stage
Figure 38: Cancer vaccine deal royalty rate value distribution, US$million – preclinical stage
Figure 39: Cancer vaccine deal royalty rate value distribution, US$million – phase I stage
Figure 40: Cancer vaccine deal royalty rate value distribution, US$million – phase II stage
Figure 41: Cancer vaccine deal royalty rate value distribution, US$million – phase III stage
Figure 42: Cancer vaccine deal royalty rate value distribution, US$million – regulatory stage
Figure 43: Cancer vaccine deal royalty rate value distribution, US$million – marketed stage
Figure 44: Cancer vaccine deal royalty rate payment value – median value by stage of development
Figure 45: Components of the typical cancer vaccine deal structure
Figure 46: Top cancer vaccine deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Figure 49: Deal type definitions

Related Reports

  • Genitourinary Partnering Terms and Agreements
    "Delivery of this report will take 1-3 days after purchase.” The Genitourinary Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the genitourinary partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter genitourinary partnering deals. The majority of deals are discovery or development stage whereby the licensee obtai...
  • Gynecology Partnering Terms and Agreements
    "Delivery of this report will take 1-3 days after purchase.” The Gynecology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the gynecology partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter gynecology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a righ...
  • Bacterial Partnering Terms and Agreements
    “Delivery of this report will take 1-3 days after purchase.” The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter bacterial partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right o...
  • Wound Healing Partnering 2009-2014
    " Delivery of this report will take 1-3 days after purchase.” Wound Healing Partnering 2009-2014 report provides understanding and access to the wound healing partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in wound healing partnering deals Top wound healing deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Wound Healing Partnering 2009-2014 provides understanding and access to the woun...
  • RSV Partnering 2009-2014
    " Delivery of this report will take 1-3 days after purchase." The RSV Partnering  2009-2014 provides understanding and access to the RSV partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of RSV partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors RSV technology. These deals tend to be multicomponent, starting with coll...